Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

1. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2021 Apr 19;dc202877. doi: 10.2337/dc20-2877. Online ahead of print. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2

2021 EvidenceUpdates

2. Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial Full Text available with Trip Pro

Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) : Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2021 Mar 26. doi: 10.1111/dom.14389. Online ahead of print. Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized

2021 EvidenceUpdates

3. Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial

Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2021 Apr 8;dc202109. doi: 10.2337/dc20-2109. Online ahead of print. Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy

2021 EvidenceUpdates

4. The beneficial short-term effects of a high-protein/low-carbohydrate diet on glycaemic control assessed by continuous glucose monitoring in patients with type 1 diabetes Full Text available with Trip Pro

on glycaemic control assessed by continuous glucose monitoring in patients with type 1 diabetes Charilaos Dimosthenopoulos et al. Diabetes Obes Metab . 2021 . Show details Display options Display options Format Diabetes Obes Metab Actions . 2021 Mar 26. doi: 10.1111/dom.14390. Online ahead of print. Authors , , , , , , Affiliations 1 Department of Clinical Nutrition, Laiko General Hospital, Athens, Greece. 2 First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian (...) : standards of medical Care in Diabetes-2020. Diabetes Care. 2020;43:S98-S110. Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986. Amiel S, Beveridge S, Bradley C, et al. Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose

2021 EvidenceUpdates

5. The effectiveness of in-hospital interventions on reducing hospital length of stay and readmission of patients with Type 2 Diabetes Mellitus: A systematic review

The effectiveness of in-hospital interventions on reducing hospital length of stay and readmission of patients with Type 2 Diabetes Mellitus: A systematic review The effectiveness of in-hospital interventions on reducing hospital length of stay and readmission of patients with Type 2 Diabetes Mellitus: A systematic review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Review Diabetes Res Clin Pract Actions . 2020 Aug 6;108363. doi: 10.1016/j.diabres.2020.108363. Online ahead of print. The effectiveness of in-hospital interventions on reducing hospital length of stay and readmission of patients with Type 2 Diabetes Mellitus: A systematic review

2021 EvidenceUpdates

6. Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis

. Bode BW, Buse JB, Fisher M, et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN((R)) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 2013;30(11):1293-7. - - - Show all 60 references Publication types Review Actions Related information Grant support LinkOut - more resources Full Text Sources Full text links [x] [x] Cite Copy (...) Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features

2021 EvidenceUpdates

7. Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2 Full Text available with Trip Pro

Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2 Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2 - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2021 Mar 9. doi: 10.1111/dom.14368. Online ahead of print. Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2 , , , , , , , , , Affiliations Expand Affiliations 1 Physicians East, PA

2021 EvidenceUpdates

8. Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study Full Text available with Trip Pro

Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History (...) citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2021 Feb 23. doi: 10.1111/dom.14362. Online ahead of print. Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study

2021 EvidenceUpdates

9. Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses

Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 Information Show (...) displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Heart Actions . 2021 Apr 8;heartjnl-2021-319243. doi: 10.1136/heartjnl-2021-319243. Online ahead of print. Predictive models for cardiovascular and kidney outcomes in patients with type 2 diabetes: systematic review and meta-analyses , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Health Research Methods, Evidence, and Impact, McMaster University, Hamilton

2021 EvidenceUpdates

10. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England Full Text available with Trip Pro

Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features (...) Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Lancet Diabetes Endocrinol Actions . 2021 May;9(5):293-303. doi: 10.1016/S2213-8587(21)00050-4. Epub 2021 Mar 30. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England , , , , , , , , , , , , , , Affiliations Expand

2021 EvidenceUpdates

11. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study Full Text available with Trip Pro

with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study Charlotte K Boughton et al. Diabetes Obes Metab . 2021 . Show details Display options Display options Format Diabetes Obes Metab Actions . 2021 Feb 19. doi: 10.1111/dom.14355. Online ahead of print. Authors , , , , , , , , , , , , , , Affiliations 1 Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. 2 (...) Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage

2021 EvidenceUpdates

12. Metformin extended release for treating type 2 diabetes mellitus

Metformin extended release for treating type 2 diabetes mellitus ACE Technology Guidances ACE Technology Guidances ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the subsidy status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the subsidy recommendations, and key clinical and economic evidence (...) which informed their deliberations. Published on 18 Jan 2021 Last Updated on 18 Jan 2021 Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has not recommended listing metformin extended release on the Standard Drug List (SDL) for treating type 2 diabetes mellitus because of limited clinical need and unfavourable cost-effectiveness compared with metformin immediate release. 25 Jan 2021 Agency for Care Effectiveness (ACE) Quicklinks © 2020 Ministry of Health Singapore Last

2021 ACE Technology Guidance (Singapore)

13. A systematic review of illness perception interventions in type 2 diabetes: Effects on glycaemic control and illness perceptions

A systematic review of illness perception interventions in type 2 diabetes: Effects on glycaemic control and illness perceptions A systematic review of illness perception interventions in type 2 diabetes: Effects on glycaemic control and illness perceptions - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging (...) Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Review Diabet Med Actions . 2021 Mar;38(3):e14495. doi: 10.1111/dme.14495. Epub 2020 Dec 30. A systematic review of illness perception interventions in type 2 diabetes: Effects on glycaemic control and illness perceptions , , , , Affiliations Expand Affiliations 1 Department of Psychological Medicine, University of Auckland, Auckland

2021 EvidenceUpdates

14. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update — The User’s Guide

Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update — The User’s Guide My Site - Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update — The User’s Guide Diabetes Canada | Clinical Practice Guidelines The Canadian Diabetes Association has become Diabetes Canada* Search: Guidelines Key Messages For Health-Care Providers For People with Diabetes Other Languages Links Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update (...) recommendations or the rationale behind their grading. Additional clinical practice tools and resources are being developed to support persons with diabetes and to help prescribers apply the updated guidelines. Questions General Are Diabetes Canada’s guidelines too glucocentric? The update on pharmacotherapy for type 2 diabetes is only one part of our clinical practice guidelines (CPG) which aim to take a holistic, patient-centred approach. Reducing microvascular and cardiovascular (CV) complications

2021 Diabetes Canada

15. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update

glycemic management of type 2 diabetes in adults: 2020 update - the user’s guide. Can J Diabetes 2020; 44:589e93. Maruthur NM, Tseng E, Hutfless S, et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med 2016;164:740e51. Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: A network meta (...) -analysis. PLoS ONE 2015;10: e0125879. Mishriky BM, Cummings DM, Tanenberg RJ. The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract 2015;109:378e88. Foroutan N, Muratov S, Levine M. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis

2021 Diabetes Canada

16. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes

options Display options Format Share Permalink Copy Page navigation Diabetes Care Actions . 2021 Apr;44(4):901-907. doi: 10.2337/dc20-2586. Epub 2021 Jan 28. A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes , , , , , , , , , Affiliations Expand Affiliations 1 Steno Diabetes Center Copenhagen, Gentofte, Denmark dorte.vistisen@regionh.dk. 2 Steno Diabetes Center Copenhagen, Gentofte, Denmark. 3 Steno Diabetes Center Aarhus, Aarhus, Denmark. 4 University of Edinburgh (...) A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close Account Logged in as: username Search: Search Save

2021 EvidenceUpdates

17. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes Full Text available with Trip Pro

Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close Account (...) Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Circulation Actions . 2021 Feb 9;143(6):540-552. doi: 10.1161/CIRCULATIONAHA.120.051898. Epub 2020 Nov 16. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes , , , , , , , , , , , Affiliations Expand Affiliations 1 National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital, Greece

2021 EvidenceUpdates

18. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial Full Text available with Trip Pro

Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable (...) Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Am J Kidney Dis Actions . 2020 Oct 29;S0272-6386(20)31072-6. doi: 10.1053/j.ajkd.2020.09.009. Online ahead of print. Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial , , , , , , Affiliations Expand Affiliations 1

2021 EvidenceUpdates

19. Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study Full Text available with Trip Pro

Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Show account info Close Account Logged (...) Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Obes Metab Actions . 2021 Jan 27. doi: 10.1111/dom.14330. Online ahead of print. Cardiovascular safety of evogliptin in patients with type 2 diabetes: A nationwide cohort study , , , , , , Affiliations Expand Affiliations 1 School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea. 2 Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Republic of Korea. 3

2021 EvidenceUpdates

20. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis

Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other (...) for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation Diabetes Res Clin Pract Actions . 2021 Feb;172:108656. doi: 10.1016/j.diabres.2021.108656. Epub 2021 Jan 9. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta

2021 EvidenceUpdates